Company Filing History:
3 out of 3,539 
1 out of 1,217 
Years Active: 1999-2011
Title: Karl G Csaky: Innovator in Ocular Therapeutics
Introduction
Karl G Csaky is a notable inventor based in Kensington, MD (US). He has made significant contributions to the field of ocular therapeutics, holding a total of 4 patents. His work focuses on innovative methods for treating ocular neovascularization and cancer, which are critical areas in medical research.
Latest Patents
One of his latest patents is titled "Therapeutic administration of the scrambled anti-angiogenic peptide C16Y." This invention addresses the issue of unregulated angiogenesis, which is linked to various pathological conditions, including tumor growth and serious ocular diseases. The peptide sequence C16Y has been discovered to inhibit ocular neovascularization and tumor growth in vivo. Unlike its counterpart C16, which stimulates angiogenesis, C16Y serves as an inhibitor, providing a promising avenue for treatment.
Another significant patent involves "Ocular therapeutic agent delivery devices and methods for making and using such devices." This invention describes ocular implant devices designed for the controlled and sustained delivery of therapeutic agents to the eye. The patent outlines both dual mode and single mode drug delivery devices, as well as fabrication techniques for these unique ocular implants.
Career Highlights
Karl G Csaky has worked with prestigious organizations, including the National Institutes of Health, a component of the US Department of Health & Human Services. His experience in these institutions has allowed him to contribute to groundbreaking research in ocular health.
Collaborations
Throughout his career, Csaky has collaborated with notable colleagues such as Michael R Robinson and Peng Yuan. These partnerships have further enhanced his research and development efforts in the field of ocular therapeutics.
Conclusion
Karl G Csaky's innovative work in ocular therapeutics has the potential to significantly impact the treatment of serious eye diseases and cancer. His patents reflect a commitment to advancing medical science and improving patient outcomes.